Opus Genetics (IRD) Change in Receivables (2022 - 2026)
Opus Genetics' (IRD) quarterly Change in Receivables came in at -$264000.0 in Q1 2026, up 45.34% year-on-year from -$181641.0 in Q1 2025, and up 71.34% on a QoQ basis from -$921000.0 in Q4 2025.
Opus Genetics (IRD) Change in Receivables (2022 - 2026) Analysis & Trends
Opus Genetics (IRD) has 5 years of Change in Receivables data on file, last reported at -$264000.0 in Q1 2026.
- On a quarterly basis, Change in Receivables rose 45.34% year-over-year to -$264000.0 in Q1 2026; TTM through Mar 2026 was -$1.3 million, a 216.7% decrease from a year earlier, with the FY2025 full-year figure at -$1.6 million, down 159.46% from the prior year.
- Change in Receivables for Q1 2026 stood at -$264000.0, up from -$921000.0 in the prior quarter.
- Over the last five years, Change in Receivables for IRD reached as high as $10.0 million in Q3 2023 and fell as low as -$9.2 million in Q4 2023.
- Historically, Change in Receivables has averaged $123642.9 across 5 years, with a median of $27500.0 in 2025.
- Across the five-year window, Change in Receivables tumbled 809.24% in 2023 and jumped 156.36% in 2025, its largest moves.
- Year by year, Change in Receivables stood at $1.3 million in 2022, then tumbled by 809.24% to -$9.2 million in 2023, then soared by 118.53% to $1.7 million in 2024, then sank by 153.99% to -$921000.0 in 2025, then surged by 71.34% to -$264000.0 in 2026.
- Per Business Quant data, the three most recent Change in Receivables figures were -$264000.0 in Q1 2026, -$921000.0 in Q4 2025, and -$483000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 75.30 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | -39.80 Mn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | -1.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Opus Genetics | 263.72 Mn | 203.72 Mn | - | -264,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -264,000.00 |
| Mar 31, 2026 | -264,000.00 |
| Dec 31, 2025 | -921,000.00 |
| Dec 31, 2025 | -921,000.00 |
| Sep 30, 2025 | -483,000.00 |
| Sep 30, 2025 | -483,000.00 |
| Jun 30, 2025 | 319,000.00 |
| Jun 30, 2025 | 319,000.00 |
| Mar 31, 2025 | -483,000.00 |
| Mar 31, 2025 | -483,000.00 |
| Dec 31, 2024 | 1.71 Mn |
| Dec 31, 2024 | 1.71 Mn |
| Sep 30, 2024 | 499,000.00 |
| Sep 30, 2024 | 499,000.00 |
| Jun 30, 2024 | -566,000.00 |
| Jun 30, 2024 | -566,000.00 |
| Mar 31, 2024 | 998,000.00 |
| Mar 31, 2024 | 998,000.00 |
| Dec 31, 2023 | -9.21 Mn |
| Dec 31, 2023 | -9.21 Mn |